Prellis Biologics Raises $35M in Series C Funding
Summary
Led by CEO Michael Nohaile, Prellis Biologics, Inc. utilizes its proprietary, high-resolution bioprinting technology to recreate and engineer human tissues in vitro. With EXIS, Prellis is able to exploit fully-human immune responses for a variety of applications including antibody discovery, immunogenicity assessment and tumor-immune models. Dr. Nohaile joins from Generate Biomedicines and succeeds Prellis Bio founder Dr. Melanie Matheu, who will assume the role of Chief Technology Officer and retain a Board seat. The company will also add two new board members: Lei Meng, Senior Therapeutics Analyst of Avidity Partners, and Nobel Prize winner James Rothman, PhD the Sterling Professor of Cell Biology at Yale University. Earlier this year, Prellis Bio announced collaboration and licensing option agreements with Sanofi and Bristol Myers Squibb.
Funding
Review available funding amount, funding date, investors, and linked company information related to Prellis Biologics Raises $35M in Series C Funding in the interactive ISVWorld profile.